Business Wire

Takeda Global Headquarters Grand Opening

2.7.2018 11:54:00 EEST | Business Wire | Press release

Share

Takeda Pharmaceutical Company Limited, (“Takeda”) (TOKYO:4502) today held the grand opening of Takeda Global Headquarters. The building, completed in March 2018, will serve as Takeda's head office for its operations worldwide.

At the grand opening, Creative Director Kashiwa Sato (SAMURAI, Inc.), Takeda's President and CEO Christophe Weber, and Takeda’s Head of Corporate Strategy and the CEO Office, Yasuhiro Fukutomi, who managed the project, took to the stage to introduce the objectives and significance of the project as the company accelerates its transformation.

“Takeda Global Headquarters symbolizes the passing on to the next generation of Takeda's unwavering identity and values as a company, with its roots in Japan, yet reaching patients worldwide," said Takeda President and CEO Weber. "Moreover, it will provide a base for our diverse workforce of around 30,000 employees across the globe where they can connect, collaborate, learn and share, in an environment designed to offer comfort and inspiration. From here in Nihonbashi, Tokyo, we will pursue our mission of contributing to better health and a brighter future for people worldwide, while nurturing our relationship with the local community.”

Kashiwa Sato said “I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s values, and its core commitment to always put patients first. In this process, I chose 'life force' as the central concept, and the eight characters for 'life', 'water', 'light', 'earth', 'trees', 'people', 'connections', and 'future' as motifs, representing this concept. Just as these basic natural elements form the wellspring that nurtures life, the bonds between people are the driving-force that enable them to tackle the biggest of challenges, and contribute to a brighter future for all. It is my hope that this building will be an inspiration to all who work here as well as to the visitors, and it will lead them to naturally want to share their thoughts on Takeda’s future.”

With Takeda Global Headquarters as a base, and a symbol of our values, we will further accelerate our transformation into becoming a global, values-based R&D-driven biopharmaceutical leader.

About Takeda Global Headquarters

Please visit the URL below for more information on Takeda Global Headquarters.
https://www.takeda.com/who-we-are/how-we-work/

Design Concept

As the embodiment of a global brand with roots in Japan, I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s DNA. These fundamental elements contribute to Takeda being the world-renowned pharmaceutical company, as well as underpinning the promise of a brighter future for all. They could also be interpreted as people’s “life force”, and it was this that I selected as the overall concept for the interior design. The concept of “life force” can also be seen to represent the fundamental point of origin of the company, and indeed, refined to reveal a vision of its future state. In this way, it can hold an important message for Takeda, and one that should be embraced and passed on to future generations. I approached the flow of movement, from the building entrance, past the reception and then on to the areas where people work, as a story of nurturing life. I chose to depict phases in this story - beginning with the source of life, followed by growth, and finally to the formation of strong connections - by associating symbolic kanji characters with each space. The characters were tuned into modern designs that convey the spirit of ”Wa” (a sense of Japanese-style harmony) which is inherent in Takeda, and applied as artwork on the walls. It is my hope that this building will be an inspiration to all who work here, and will lead them to naturally want to share their thoughts on Takeda’s future with other people that they meet on a daily basis.

Kashiwa Sato, Creative Director
http://kashiwasato.com/

Photos are available upon request.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye